We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+19.19%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$783M
AUM Growth
+$36.9M
Cap. Flow
-$49.7M
Cap. Flow %
-6.35%
Top 10 Hldgs %
34.67%
Holding
106
New
16
Increased
38
Reduced
39
Closed
13

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$22.4M
2
KROS icon
Keros Therapeutics
KROS
+$11M
3
SYK icon
Stryker
SYK
+$9.66M
4
RCUS icon
Arcus Biosciences
RCUS
+$9.62M
5
DGX icon
Quest Diagnostics
DGX
+$8.21M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$16M
2
ELV icon
Elevance Health
ELV
+$15M
3
HUM icon
Humana
HUM
+$11.2M
4
COR icon
Cencora
COR
+$8.56M
5
THC icon
Tenet Healthcare
THC
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$71.5B
$37.5M 4.78%
447,196
-104,396
-19% -$8.23M
PODD icon
2
Insulet
PODD
$9.79B
$37.2M 4.74%
159,689
-19,616
-11% -$4.03M
LLY icon
3
Eli Lilly
LLY
$1.06T
$35.8M 4.57%
40,384
+8,730
+28% +$7.85M
COO icon
4
Cooper Companies
COO
$14.5B
$32.3M 4.12%
292,593
-15,805
-5% -$1.54M
KROS icon
5
Keros Therapeutics
KROS
$221M
$24.5M 3.13%
421,782
+223,155
+112% +$11M
TFX icon
6
Teleflex
TFX
$5.98B
$23.8M 3.04%
+96,144
New +$22.4M
UTHR icon
7
United Therapeutics
UTHR
$23.1B
$22.9M 2.93%
64,031
-47,350
-43% -$16M
MNKD icon
8
MannKind Corp
MNKD
$1.32B
$20.8M 2.65%
3,304,085
+894,486
+37% +$5.14M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$5.93B
$18.9M 2.41%
755,244
+108,102
+17% +$2.63M
VRNA
10
DELISTED
Verona Pharma
VRNA
$18M 2.3%
626,452
+31,063
+5% +$764K
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.7M 2.26%
241,575
+56,547
+31% +$4.25M
EWTX icon
12
Edgewise Therapeutics
EWTX
$4.73B
$17.5M 2.24%
657,070
+82,553
+14% +$1.64M
LBPH
13
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$16.4M 2.09%
491,272
-202,906
-29% -$6.99M
RCUS icon
14
Arcus Biosciences
RCUS
$3.64B
$15.7M 2%
1,025,754
+610,219
+147% +$9.62M
THC icon
15
Tenet Healthcare
THC
$21.1B
$15.6M 1.99%
93,753
-55,174
-37% -$8.34M
TVTX icon
16
Travere Therapeutics
TVTX
$5.78B
$15.2M 1.94%
1,086,067
+116,175
+12% +$1.21M
NBIX icon
17
Neurocrine Biosciences
NBIX
$16.6B
$15M 1.91%
129,840
+14,670
+13% +$2.01M
PCVX icon
18
Vaxcyte
PCVX
$8.64B
$14.9M 1.9%
130,249
-19,942
-13% -$1.8M
BDX icon
19
Becton Dickinson
BDX
$48.2B
$14.5M 1.85%
60,011
-8,156
-12% -$1.91M
ABT icon
20
Abbott
ABT
$187B
$14.1M 1.8%
123,601
+1,688
+1% +$185K
DAWN
21
DELISTED
Day One Biopharmaceuticals
DAWN
$12.9M 1.64%
924,140
+15,318
+2% +$219K
AGIO icon
22
Agios Pharmaceuticals
AGIO
$1.93B
$12.7M 1.62%
285,099
-161,317
-36% -$7.33M
GILD icon
23
Gilead Sciences
GILD
$165B
$10.8M 1.38%
129,025
+4,025
+3% +$307K
SDGR icon
24
Schrodinger
SDGR
$1.36B
$10.4M 1.32%
559,105
-162,268
-22% -$3.33M
SYK icon
25
Stryker
SYK
$130B
$10.1M 1.29%
+28,000
New +$9.66M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Parkman Healthcare Partners held 106 positions worth $783M, up 4.9% from $747M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $49.7M in Q3 2024, closing 13 positions and reducing 39 holdings. Its most notable exit was Elevance Health, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Teleflex worth $23.8M.

  • Parkman Healthcare Partners's largest Q3 2024 buy was Teleflex: 96,144 shares worth $23.8M.
  • Parkman Healthcare Partners added most to Keros Therapeutics in Q3 2024, an estimated $11M increase.
  • Parkman Healthcare Partners's biggest Q3 2024 reduction was United Therapeutics, cutting an estimated $16M.
  • Parkman Healthcare Partners fully exited Elevance Health in Q3 2024, selling an estimated $15M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $783M portfolio in Q3 2024.
  • Parkman Healthcare Partners opened 16 new positions and closed 13 in Q3 2024.
  • Parkman Healthcare Partners's portfolio value rose 4.9% quarter-over-quarter to $783M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2024, filed 14 Nov 2024.